Raphael Ognar

Company: NKILT Therapeutics

Job title: President & CEO, Co-founder

Seminars:

Chimeric ILT-Receptor (CIR™) Technology Effectively Targets HLA-G+ Hematologic & Solid Tumors for Fit-for- Purpose Activation of NK Cells 12:30 pm

Diving on how CIR™NK cells with fit-for-purpose activation can efficiently and persistently target cancer cells across multiple tumors Understanding in vivo performance and functional activity of CIR™NK cells in leukemia and solid tumorsRead more

day: Day 2 -Track A - AM

Industry Leader’s Fireside Chat: Discussing Present Advancements & Challenges in the Natural Killer Space to Envision the Future of NK Therapy 8:30 am

Discussing key advancements in the NK space to highlight the therapeutic potential of NK biology Sharing the latest findings in NK therapy and what this means for this field What are the biggest hurdles in this space that still need to be overcome?Read more

day: Day 1 AM